AbbVie Inc., Pfizer Inc., and Sanofi Dominated the Global Adenomyosis Drugs Market in 2021

The Global Adenomyosis Drugs Market is expected to grow with a CAGR of 5.9% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adenomyosis-drugs-market

The global adenomyosis drugs market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.  

The major players dealing in the global adenomyosis drugs market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, awards, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.  

For instance:

  • In September 2020, AbbVie Inc. announced that FDA approved ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules, elagolix capsules), the first oral medication for the management of heavy menstrual bleeding due to uterine fibroids in premenopausal women. This has increased the product portfolio of the company and will support the revenue of the company

AbbVie Inc. is the dominating player in the global adenomyosis drugs market. The other key players existing in the market are Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.  

AbbVie Inc.

AbbVie Inc. is headquartered in Illinois, U.S., and was founded in the year 2013. The company is a research-driven biopharmaceutical company having a great focus on treating diseases in order to make a remarkable impact on people's lives. The various products of the company include AndroGel (Testosterone Gel), CREON (Pancrelipase) Delayed-Release Capsules, DUOPA (Carbidopa/Levodopa Enteral Suspension), HUMIRA (Adalimumab), LUPRON DEPOT (leuprolide Acetate for Depot Suspension) URO, ORILISSA (elagolix), Lupaneta Pack Leuprolide Acetate for Depot Suspension, Lupaneta Depot- PED, Lupaneta Depot-RO, Minastrin 24 Fe (norethindrone acetate/ethinyl estradiol), Taytulla, Lo Loestrin Fe, Estrostep FE (norethindrone acetate/ethinyl estradiol)  among others. The market-focused product categories are ORILISSA (elagolix), Lupaneta Pack Leuprolide Acetate for Depot Suspension, Lupaneta Depot- PED, Lupaneta Depot-RO, Minastrin 24 Fe (norethindrone acetate/ethinyl estradiol), Taytulla, Lo Loestrin Fe, Estrostep FE (norethindrone acetate/ethinyl estradiol).

For instance,

  • In November 2020, seven women's health-focused organizations – the American College of Obstetricians and Gynaecologists (ACOG), the Endometriosis Association, AbbVie, HealthyWomen, the International Pelvic Pain Society (IPPS), GE Healthcare and Black Women's Health Imperative (BWHI) – announced the formation of the Alliance for Endometriosis to improve the lives of the one in 10 women of reproductive age living with this disease in the United States. The Alliance will then create a program with the goal of reducing – or eliminating – the stigma associated with endometriosis and encouraging more productive patient and physician conversations that lead to faster diagnoses and improved treatment options and experiences

The company has a wide presence across the Americas, Europe, Africa, Asia, and Oceania. In addition, the company also generates its revenue from various subsidiaries, including Knoll Pharmaceutical Company (New Jersey), AbbVie S.A. (Argentina), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium), and AbbVie SAS (Colombia), among others.

Pfizer Inc.

Pfizer Inc. is headquartered in New York, U.S., and was founded in the year 1849. The company focuses on providing quality standards, safety, and value in the discovery, development, and manufacturing of healthcare products, including innovative medicines and vaccines. The various products of the company include Accupril, Accuretic, Adenosine, Advil, Alavert, Benefix, Bleomycin, Panzyga, DEPO-MEDROL (Methylprednisolone Acetate Injectable Suspension), ARTHROTEC, FELDENE, PREMPRO/PREMPHASE, among others. ARTHROTEC, FELDENE, PREMPRO/PREMPHASEis are the market-focused categories.

For instance,

  • In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.

The company has a presence across North America, Asia Pacific, South America, Europe, the Middle East and Africa. In addition, the company also generates its revenue from various subsidiaries, including Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V.(Netherlands), Pfizer Australia Superannuation Pty Ltd ( Australia), Pfizer Dominicana, S.A.(Dominican Republic) and Pfizer Egypt S.A.E.(Egypt), among others.

Sanofi

Sanofi is headquartered in Paris, France, and was founded in the year 1973. The company focuses on patient needs and is engaged in the research development, manufacture, and marketing of therapeutic solutions. The company operates various business segments such as pharmaceutical, vaccine GBU, and costumer healthcare GBU, where pharmaceutical is the market-focused business segment. The various product categories of the company include diabetes and cardiovascular diseases, specialty care, and vaccines, where specialty care is the market-focused category.  

For instance,

  • In September 2021, Sanofi entered into a definitive merger agreement with Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi's strategy to continue to grow its General Medicines core assets.

The company has a presence across Americas, Europe, Asia-Pacific, and the Middle East and Africa. In addition, the company also generates its revenue from various subsidiaries including Sanofi Pasteur (SA), Sanofi Chimie(France), Sanofi Winthrop Industrie, and Sanofi-Aventis Recherche & Développement(SA), Sanofi Pasteur, Inc., (SA), Sanofi-Aventis Deutschland GmbH (Austria), Sanofi Pasteur Limited (SA). and others.